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Musculoskeletal (MSK) complaints are very common 
in children, who present to general practitioners, 
paediatricians and orthopaedic surgeons. Studies 
have reported that they may occur in 4 - 30% of the 
community. A Scottish study showed that 1 in every 
58 children presenting to a paediatric accident and emergency unit 
had limping as their primary complaint, and a survey of adolescents 
in British Columbia revealed that MSK complaints were viewed as 
the most common health concern after acne.[1-4] The differential 
diagnosis for a child presenting with MSK pain ranges from dreadful 
to completely benign (Table 1). 
An accurate diagnosis of juvenile idiopathic arthritis (JIA) depends 
on a good clinical approach, clues derived from the history and 
examination, and pattern recognition, which will assist the clinician 
in making the diagnosis. A thorough history and examination 
are the most important tools to make the diagnosis of JIA, where 
early diagnosis and treatment have been shown to directly improve 
outcomes.[5]  Children are constantly growing and developing, and 
changing milestones, anatomy and physiology increase the difficulty 
of making the diagnosis of JIA. 
Methods
This brief review summarises the available and relevant evidence 
on the diagnosis and management of JIA in the South African (SA) 
context and is intended to assist the non-specialist in the identification, 
management and referral of these patients. Sources of relevance were 
drawn from published medical literature (searched via Medline), 
authoritative texts and online resources on paediatric rheumatology.
ARTICLE 
Juvenile idiopathic arthritis – an update 
on its diagnosis and management
C Scott, MB ChB, FCPaed (SA), Grad Cert Paed Rheum (UWA); N Brice, MB ChB, Dip HIV Man (SA), FCPaed (SA)
Paediatric Rheumatology, Institute of Child Health, Red Cross War Memorial Children’s Hospital and University of Cape Town, South Africa 
Corresponding author: C Scott (chris.scott@uct.ac.za)
Juvenile idiopathic arthritis (JIA) is the most common form of chronic arthritis in children and the most common cause of musculoskeletal 
disability in children. Early diagnosis may be challenging, but it is essential to ensure good outcomes. This review proposes an approach to 
the investigation and diagnosis of JIA. It also gives a summary of the latest available evidence-based treatment for this disease.
S Afr Med J 2015;105(12):1077. DOI:10.7196/SAMJ.2015.v105i12.10223
Table 1. Common causes of joint pain
• Reactive arthritis 
• Juvenile idiopathic arthritis
• Septic arthritis/osteomyelitis
• Haemarthrosis (e.g. haemophilia)
• Infections (e.g. tuberculosis)
• Malignancy (e.g. acute lymphoblastic leukaemia)
• Rheumatic fever
• Benign nocturnal MSK pains of childhood (growing pains)
• Benign hypermobility syndrome
• Mechanical, e.g. Osgood-Schlatter disease, slipped upper-femoral 
epiphysis
• Avascular necrosis (e.g. Perthes disease)
• Trauma
Table 2. Juvenile idiopathic arthritis subtypes
JIA subtype Characteristics
Oligoarticular Younger child
More common in females than in males
1 - 4 affected joints in first 6 months
ANA positive in up to 70%
Uveitis – common
Extended oligoarticular >4 joints after first 6 months
Polyarticular RF 
negative
≥5 affected joints in first 6 months
RF negative
Younger child
More common in females than in males
ANA positive in ~40%
Polyarticular RF 
positive
≥5 joints in first 6 months
RF positive × 2 (3 months apart)
More common in females than in males
Adolescents
Enthesitis-related 
arthritis
HLA B27 positive
Sacroiliitis
Inflammatory backache
Family history of HLA B27-related disease
Usually older boys (>7 years)
Psoriatic arthritis Psoriasis 
Dactylitis
Psoriasis in 1st-degree relative
Nail pitting
Systemic arthritis Fever – daily
Rash
Hepatosplenomegaly
Serositis
Raised ferritin
Complicated by macrophage activation 
syndrome
HLA = human leukocyte antigen; ANA = antinuclear antibody; RF = rheumatoid factor.
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Epidemiology 
JIA is the most common chronic MSK condition in children and 
the most common cause of MSK disability. Although it is perceived 
as a rare disease it is no less common than many other childhood 
diseases such as epilepsy and diabetes, and community-based studies 
indicate that a prevalence of between 1 and 4 per 1 000 children is 
affected.[6] The wide variation in prevalence rates between studies 
could in part be accounted for by differences in study design and 
lack of standardised definitions of JIA in earlier studies. Under-
diagnosis and delays in presentation are thought to account for the 
low prevalence in hospital- and clinic-based studies. 
Terminology and classification
JIA is the World Health Organization (WHO)’s accepted terminology 
for children <16 years of age who have chronic arthritis (lasting 
>6 weeks) and in whom no other specific cause of arthritis can 
be identified.[7] The terms juvenile chronic arthritis and juvenile 
rheumatoid arthritis are outdated and no longer preferred. Studies 
from developing countries such as SA and India appear to suggest 
that polyarticular JIA is more prevalent in these populations than 
oligoarticular JIA, which predominates in populations in Europe and 
the USA.[8] 
For the purpose of classification, JIA is divided into 7 heterogeneous 
subtypes with specific clinical and pathophysiological characteristics 
(Table 2). Knowledge of patterns of JIA is useful in making an accurate 
diagnosis. A swollen knee and uveitis in a young girl, for instance, is 
typical of oligoarticular JIA. An older boy with Achilles insertion pain 
or arthritis of the first metatarsophalangeal joint is typical of juvenile 
enthesitis-related arthrtitis (ERA). Dactylitis and asymmetrical large- 
and small-joint arthritis are seen in patients with psoriatic arthritis, 
whereas symmetrical small-joint involvement in an older girl is 
typical of rheumatoid factor (RF)-positive polyarticular JIA.
Pathophysiology
The cause of JIA is not known, although it is accepted that some type 
of interplay between environmental factors (e.g. infections or the gut 
microbiome) and complex genetic factors leads to a disturbance in 
the balance between immune tolerance and inflammation. Certain 
human leukocyte antigen (HLA) (class I and II) and non-HLA genes 
have been associated with different types of JIA.[9] Some subtypes of 
JIA appear to be more autoimmune in their pathophysiology than 
others, with adaptive and humoral immunity playing a major part. 
RF-positive polyarticular JIA, for instance, is strongly associated with 
the presence of antibodies against RF and cyclic-citrullinated peptide 
Table 3. Taking a history in suspected juvenile idiopathic arthritis
Onset of pain Pain with sudden onset suggests acute conditions such as an injury or septic arthritis. JIA often has a very 
indolent onset and it is sometimes difficult for the child or parent to remember when the pain started. It is very 
important to note that the absence of reported pain does not exclude arthritis.
Timing of pain Early-morning stiffness and so-called ‘gelling’ suggest inflammatory pain. The child only limps first thing in the 
morning and recovers for the rest of the day. 
Pain that improves with rest and worsens with activity is usually mechanical.
Nocturnal pain, commonly in the lower limbs, which disappears by morning, never occurs during the day and 
is not associated with any other symptom, is typical of benign nocturnal limb pains of childhood, also known as 
growing pains. 
Nocturnal bone pain associated with fever, malaise, pallor and petechiae would obviously suggest haematological 
malignancy. These patients have persistent constitutional or MSK complaints during the day.
Patients with benign hypermobility suffer from pain in the evening after an active day, while their symptoms 
may improve with rest.
Intensity of pain The pain caused by JIA is not frequently reported as severe. Entheseal inflammation or tenosynovitis, however, 
can be acutely painful despite a relative absence of clinical signs of swelling or joint limitation. 
The pain in amplified pain syndromes or complex regional pain syndromes can be extremely intense and persist 
throughout the day, causing major disability. 
Septic arthritis is also acutely painful, frequently resulting in a frozen joint, where the child expresses anxiety at 
the prospect of motion of the joint.
Disability Children with early JIA frequently find ways to continue their activities of daily living, and function relatively 
well. 
Children with amplified pain syndromes may have severe functional impairment, despite minor clinical findings. 
Response to medication Children with JIA or osteoid osteomas frequently respond well to non-steroidal anti-inflammatory drugs. This is 
not the case with conditions such as amplified pain or bone pain caused by malignancy.
Other systemic features Raynaud’s phenomenon, which is common in children with scleroderma and SLE, is frequently not reported 
until direct enquiry. The presence of psoriasis, gastrointestinal symptoms, fever, rash or a bleeding tendency can 
all point in the direction of an underlying cause for arthritis.
Family history A family history of psoriasis is essential. Similarly, a family history of ankylosing spondylitis, inflammatory 
bowel disease and SLE may increase the risk of these conditions.
A family history of sickle cell disease is important, especially in a child presenting with dactylitis, septic arthritis 
or avascular necrosis. 
Social history and exposure to 
infectious diseases
A social history of infections such as HIV or TB is an essential component. A preceding history of infection, 
especially viral or dysenteric, is crucial.
SLE = systemic lupus erythematosus; TB = tuberculosis.
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(CCP), and CD4 T-cells play a role in propagating the inflammatory 
response. Systemic JIA, however, is an autoinflammatory disease 
driven by abnormalities of the innate immune system, with neutrophils 
and macrophages playing the major pathogenic roles. 
Approach to diagnosis
Taking a history in a child with suspected JIA
A good history with appropriate focus on the relevant symptoms and 
signs of JIA and other conditions in the differential diagnosis is very 
important in diagnosing JIA. Table 3 summarises the relevant aspects 
of history-taking in a patient with suspected JIA.
Examination
A child presenting with joint pain or MSK symptoms should have a 
full examination of all systems and not just of the MSK system. A basic 
paediatric examination, including anthropometry and vital signs (as 
well as blood pressure), is crucial. This not only helps to diagnose or 
exclude non-rheumatic illnesses that may present with MSK pain, but 
also to find signs associated with many of the rheumatic diseases. Red 
flag signs for malignancy include the following: fever, malaise, weight 
loss, pallor, petechiae, nocturnal bone pain, constant symptoms, 
unexplained bruising and lymphadenopathy. 
It is important to note that children with JIA (or their parents) 
do not always report pain or limitation in their joints, especially 
the younger age groups. It is crucial that a thorough examination is 
undertaken to identify all active joints. 
The MSK examination should start with the screening examination 
known as the paediatric gait arms legs spine (PGALS). This validated 
screening tool has been designed to facilitate the rapid initial assessment 
of a child with MSK pain. It is quick and easy to do and easily accepted 
by patients. The PGALS starts with 3 screening questions and moves 
to several manoeuvres that are specifically choreographed to reveal 
abnormalities in the MSK system in children. It is summarised in Table 
4 and is published here with permission from the authors.[10] 
If an abnormality is identified on PGALS, a full MSK examination 
should be undertaken, including a thorough examination of all 
joints. Guidelines on specific joint examinations can be viewed 
online (see Online resources below). This web-based resource 
is focused on providing information to non-rheumatologists on 
the examination and management of rheumatic diseases. Specific 
points of interest in the examination of children with JIA are given 
in Table 5.
Laboratory investigations
Laboratory investigations in JIA are used mainly to exclude other 
diagnoses or to investigate complications of JIA or its treatment. The 
minimum investigations are given in Table 6.
Conventional radiography
Radiographs in children with MSK disease are a standard first-
line investigation that is widely available and affordable. In 
the context of the diagnosis of JIA, radiographs are useful in 
Table 4. Paediatric gait, arms, legs, spine screening 
examination
Screening 
questions
Do you (or does your child) have any pain or stiffness 
in the joints, muscles or back?
Do you (or does your child) have any difficulty getting 
dressed without any help?
Gait Do you (or does your child) have any difficulty going 
up and down stairs?
Observe the child walking and turning. 
‘Walk on your tip-toes/walk on your heels.’
Arms ‘Put your hands out in front of you.’
‘Turn your hands over and make a fist.’
‘Pinch your index finger and thumb together.’
‘Touch the tips of your fingers with your thumb.’
Squeeze metacarpophalangeal joints.
‘Put your hands together/put your hands back-to-back.’
‘Reach up and touch the sky.’
‘Look up at the ceiling.’
‘Put your hands behind your neck.’
Legs Feel for effusion at the knee.
‘Bend and then straighten your knee.’ (Active 
movement of knees and examiner feels for crepitus.)
Passive flexion (90°) with internal rotation of the hip.
Spine ‘Open your mouth and put three of your fingers in 
your mouth.’
Lateral flexion of the spine: ‘Try to touch your shoulder 
with your ear.’
Observe spine from behind.
‘Can you bend and touch your toes?’: observe curve of 
spine from side and behind.
Further details are available, with a video demonstration of PGALS performed on a normal 
child, at www.arthritisresearchuk.org/health-professionals
Table 5. The examination of a child with juvenile idiopathic arthritis
Pain Extreme pain with motion could indicate a fracture 
or septic arthritis.
Mild pain with swelling or loss of range of motion is 
usual for JIA. 
Amplified pain syndromes may have severe 
hyperaesthesia. 
Range of 
motion
A child should have a full range of motion in all joints. 
Significant and longstanding arthritis will frequently 
cause deviations from the full range of motion. 
Swelling Swelling may be hard to assess, especially in the 
elbows, shoulders and ankles of younger children. 
When swelling is identified, it is important to 
consider the nature of the swelling: fluid is fluctuant, 
synovium boggy and compressible.
Atrophy Atrophy can be subtle and a sign of functional loss 
in a limb. 
Colour Joints are frequently warm in chronic and acute 
arthritis, but a red joint is highly suggestive of septic 
arthritis or osteomyelitis. 
Localised 
growth 
disturbances
Longstanding arthritis causes localised growth 
disturbances. The affected limb grows longer and thicker 
than the unaffected limb. Leg length discrepancy is a 
useful marker of chronic arthritis. Evaluating the child 
from behind for pelvic tilt can assess this. 
Eye 
examination
Certain types of JIA are associated with uveitis. 
While a painful red eye is associated with enthesitis-
related arthritis, the uveitis of JIA can be completely 
asymptomatic. Initially, slit lamp examination is 
required to identify uveitis. Later in the disease, 
a distorted pupil (caused by posterior synechiae), 
glaucoma or cataracts may be present
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excluding other causes of MSK pain, e.g. fractures or other bony 
lesions such as osteomyelitis or tumours. They can also give 
specific information on joint space narrowing, bone erosions, 
joint alignment, subluxation or ankylosis. It is important to note 
that the absence of abnormalities on X-ray examination does not 
exclude acute or chronic arthritis.
Other imaging modalities are summarised in Table 7.
Treatment of JIA
Early recognition of JIA and referral to specialist and multidisciplinary 
services for management improves the prognosis. In all cases the goal 
of treatment is complete disease remission and normal physical and 
social development. The many new medications currently available 
for the treatment of JIA make this achievable.
Non-pharmacological therapy
Physiotherapy and occupational therapy are essential in the 
management of JIA. These therapies improve joint range of motion 
and mobility and thereby prevent permanent deformity. They can 
help manage pain and encourage children to exercise within the 
limits of their abilities. This physical activity is safe and important 
in improving the quality of life of children with JIA. Social workers 
and mental health experts are often also needed to address the 
psychosocial impact of pain and chronic illness on the child and 
family unit. 
Pharmacological therapy
Non-steroidal anti-inflammatory drugs (NSAIDs)
NSAIDs are used for the management of joint pain and stiffness. All 
NSAIDs are equally effective and choice depends on cost, tolerability, 
dosing schedule and formulation. Gastrointestinal side-effects are 
common and patients requiring long-term NSAIDs should have 
regular renal and liver function monitoring.
Corticosteroids
Systemic oral and parenteral corticosteroids are used in the treatment 
of JIA, usually as bridging therapy while disease-modifying anti-
rheumatic drug (DMARD) regimens take effect. They are particularly 
useful in severe polyarthritis and systemic JIA. Importantly, they 
do not induce remission, and care should always be taken to 
minimise exposure, given the potential side-effects of long-term use. 
Concurrent calcium and vitamin D supplementation is necessary to 
prevent osteopenia.
Intra-articular steroid (IAS) injections have been shown to 
induce sustained remission when used as monotherapy or in 
conjunction with methotrexate.[11] Triamcinolone hexocetonide 
is thought to have superior efficacy to methylprednisolone 
acetate. IAS injections are usually well tolerated, but in young 
children should preferably be done under sedation or general 
anaesthetic. Subcutaneous atrophy at the injection site can occur 
in approximately 2% of cases.[12] 
Disease modifying anti-rheumatic drugs 
DMARDs are used as maintenance therapy to control disease activity. 
They are safe and effective in children and their use ideally limits the 
need for long-term NSAIDs and corticosteroids. Early introduction 
of DMARDs has been shown to decrease disease severity and 
improve prognosis. Table 8 summarises the important prescribing 
details of synthetic DMARDs.[13-15] 
Table 6. Special investigations in juvenile idiopathic arthritis
Full blood count Useful in differentiating the inflammatory 
from the non-inflammatory disease. 
Thrombocytopenia and peripheral blood 
smear may identify haematological 
malignancies.
ESR Fibrinogen produced by the liver in response to 
cytokine stimulation causes high ESR seen in 
inflammation. Nonspecific inflammatory marker, 
more useful in monitoring of inflammatory 
diseases than diagnosis.
CRP Produced in the liver in response to cytokine 
stimulation (IL-6, IL-1 and TNF). The 
advantages of CRP measurement: it is not 
influenced by as many variables as the ESR. 
ANA/ANF Although they are generally ubiquitous and 
present in many individuals who do not have 
autoimmune disease, high titres are associated 
with autoimmune conditions. Some subtypes 
of JIA are associated with positive tests for 
ANA.
RF and anti-CCP This is the most over-requested and over-
interpreted test in children suspected of having 
a rheumatic disease. As a screening test for JIA 
it is of virtually no value. A small subgroup of 
children with RF-positive polyarticular disease 
will have a positive RF; this test is useful in 
classifying this cohort.
HLA B27 This major histocompatibility complex type 1 
antigen is strongly associated with enthesitis-
related arthritis. It also occurs with greater 
frequency in children with psoriatic arthritis, 
inflammatory bowel disease, reactive arthritis 
and acute anterior uveitis. It is a useful test if 
one of these conditions is suspected on clinical 
grounds, but not a good screening tool in the 
general population.
ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; ANA = antinuclear 
antibodies; ANF = antinuclear factor; RF = rheumatoid factor; anti-CCP = cyclic citrullinated 
peptide antibodies; TNF = tumour necrosis factor; IL = interleukin.
Table 7. Ultrasound and magnetic resonance imaging in 
juvenile idiopathic arthritis
Ultrasound Useful in the diagnosis of children suspected of having 
inflammatory joint disease. Gives good anatomical 
detail; can also reliably show joint effusions, synovial 
hypertrophy, inflammation and inflamed tendon 
sheaths and entheses. Early erosions and osteophytes 
can be identified. Quality depends on experience and 
training of ultrasonographer.
MRI MRI gives very accurate information on bone and 
soft-tissue structure of the joint. Sensitive tool 
for assessing inflammation and oedema. Utility 
limited by cost and availability as well as the need 
for sedation or anaesthetic in young children. 
Gold standard examination in terms of detail and 
accuracy.
MRI = magnetic resonance imaging.
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Biologic agents
The advent of biologic agents has significantly enhanced the treatment 
options for children with JIA and made complete disease remission 
an achievable outcome. The choice of agent depends on JIA subtype, 
but patient preference with regard to route and frequency of admission 
should also be considered. These agents are expensive and access to them 
requires careful motivation to the healthcare system involved. Table 9 
summarises the important prescribing details of biologic DMARDs.[16-21] 
Conclusion
JIA is not a rare disease and the complications of untreated JIA are 
significant. All physicians dealing with children should know when 
to suspect or diagnose this condition and perform the relevant 
investigations. Early appropriate referral will improve outcomes in 
patients with this disease. The modern arsenal of investigations and 
management greatly improves the outcome of patients with JIA. 
Other causes of joint pain or MSK morbidity in children range from 
benign to potentially life threatening.
Practice points
• MSK complaints are very common in children.
• Early and correct diagnosis and referral of patients with JIA are 
important.
• JIA is predominantly a clinical diagnosis based on pattern recog-
nition.
• RF has no value in screening for patients with JIA.
• Remission can be achieved in the majority of patients using 
traditional DMARD therapy.
• Targeted cytokine therapy such as tumour necrosis factor 
inhibitors offers good therapeutic options to those not responding 
to traditional DMARDs.
References
1. De Inocencio J. Epidemiology of musculoskeletal pain in primary care. Arch Dis Child 2004;89(5):431-
434. [http://dx.doi.org/10.1136/adc.2003.028860]
2. Foster HE, Cabral DA. Is musculoskeletal history and examination so different in paediatrics? Best 
Pract Res Clin Rheumatol 2006;20(2):241-262. [http://dx.doi.org/10.1016/j.berh.2005.11.001]
3. Goodman J, McGrath P. The epidemiology of pain in children and adolescents: A review. Pain 
1991;46(3):247-264. [http://dx.doi.org/10.1016/0304-3959(91)90108-A]
4. Fischer S, Beattie T. The limping child: Epidemiology, assessment and outcome. J Bone Joint Surg Br 
1999;81(6):1029-1034. [http://dx.doi.org/10.1302/0301-620X.81B6.9607]
Table 8. Synthetic disease-modifying anti-rheumatic drugs
DMARD Dosing Common side-effects Monitoring Comments
MTX 15 mg/m2 weekly po or 
subcutaneously
Nausea and vomiting, 
mouth ulcers, transient 
transaminitis
FBC and LFTs every 
3 months
Folic acid supplementation prevents 
GIT side-effects and ulcers
Subcutaneous dosing can overcome 
poor response to oral therapy or 
GIT side-effects
Sulphasalazine 20 - 25 mg/kg twice daily po Rash, GIT upset, 
myelosuppression, liver 
function abnormalities 
FBC and LFTs every 
3 months
Possible additive hepatotoxicity 
with MTX
Chloroquine 5.0 - 6.5 mg/kg daily po GIT upset, rash, headache, 
visual changes
FBC, LFTs and U and 
E every 3 months
Test visual acuity annually
Leflunomide Loading dose: 100 mg 
daily × 3 doses po
Maintenance dose: 20 mg daily po
GIT upset, headache, rash, 
alopecia
FBC and LFTs every 
3 months
Consider when  MTX is not  
tolerated
GIT = gastrointestinal; FBC = full blood count; LFT = liver function test; U and E = urea and electrolytes; MTX = methotrexate.
Table 9. Biologic disease-modifying anti-rheumatic drugs
Class Drugs Administration Common side-effects Precautions Monitoring
TNF inhibitors Etanercept
Adalimumab
Infliximab
Golimumab
Etanercept S/C once 
weekly
Adalimumab  S/C every 
2 weeks
Infliximab IV 2 - 8-weekly
Golimumab S/C monthly
Hypersensitivity 
infusion reactions
For all biologics:
omit biologic 
during active 
infections 
Avoid in TB
For all biologics: TB 
screening before starting, 
then annually
FBC, LFT, U and E every 
3 months
IL inhibitors Anakinra (IL-1)
Tocilizumab (IL-6)
Canakinumab (IL-1β)
Anakinra S/C daily
Tocilizumab IV every 
2 weeks 
Canakinumab S/C 
monthy
Injection site or 
infusion 
reactions
Avoid live vaccines Use MTX concomitantly 
to prevent 
immunogenicity
B-cell inhibitor Rituximab IV every week × 2 doses Infusion reactions CD19 count for rituximab
T-cell 
co-stimulatory 
modulator
Abatacept IV once monthly Infusion reactions 
uncommon
IL = interleukin; IV = intravenous; S/C = subcutaneous.
CONTINUING MEDICAL EDUCATION
7       December 2015, Vol. 105, No. 12
5. Albers HM, Wessels JA, van der Straaten RJ, et al. Time to treatment as an important factor for the 
response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum 2009;61(1):46-51. [http://
dx.doi.org/10.1002/art.24087]
6. Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis: Why does it vary so much? J 
Rheumatol 2002;29(7):1520-1530.
7. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology 
classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol 
2004;31(2):390-392.
8. Weakley K, Esser M, Scott C. Juvenile idiopathic arthritis in two tertiary centres in the Western Cape, 
South Africa: University of Cape Town; 2011. Pediatr Rheumatol Online J  2012;10(1):35. [http://
dx.doi.org/10.1186/1546-0096-10-35]
9. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 2011;377(9783):2138-2149. 
[http://dx.doi.org/10.1016/S0140-6736(11)60244-4]
10. Foster HE, Kay LJ, Friswell M, Coady D, Myers A. Musculoskeletal screening examination (pGALS) 
for school-age children based on the adult GALS screen. Arthritis Rheum 2006;55(5):709-716. [http://
dx.doi.org/10.1002/art.22230]
11. Zulian F, Martini G, Gobber D, Agosto C, Gigante C, Zacchello F. Comparison of intra-articular 
triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis. 
Rheumatology (Oxford) 2003;42(10):1254-1259. [http://dx.doi.org/10.1093/rheumatology/keg358]
12. Scott C, Meiorin S, Filocamo G, et al. A reappraisal of intra-articular corticosteroid therapy in juvenile 
idiopathic arthritis. Clin Exp Rheumatol 2010;28(5):774-781.
13. Beresford M, Baildam E. New advances in the management of juvenile idiopathic arthritis – 1: Non-
biological therapy. Arch Dis Child Educ Pract Ed 2009;94(5):144-150. [http://dx.doi.org/10.1136/
adc.2008.144576]
14. Gowdie PJ, Shirley M. Juvenile idiopathic arthritis. Pediatr Clin North Am 2012;59(2):301-327. [http://
dx.doi.org/10.1016/j.pcl.2012.03.014]
15. Takken T, van der Net JJ, Helders PP. Methotrexate for treating juvenile idiopathic arthritis. Cochrane 
Database Syst Rev 2001;(4):CD003129. [http://dx.doi.org/10.1002/14651858.cd003129]
16. Beresford M, Baildam E. New advances in the management of juvenile idiopathic arthritis – 2: The 
era of biologicals. Arch Dis Child Educ Pract Ed 2009;94(5):151-156. [http://dx.doi.org/10.1136/
adc.2009.170860]
17. Giannini E, Ilowite N, Lovell D, et al. Long‐term safety and effectiveness of etanercept in children 
with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009;60(9):2794-2804. [http://
dx.doi.org/10.1002/art.24777]
18. Katsicas MM, Russo RA. Use of adalimumab in patients with juvenile idiopathic arthritis refractory to 
etanercept and/or infliximab. Clin Rheumatol 2009;28(8):985-988. [http://dx.doi.org/10.1007/s10067-
009-1162-7]
19. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled 
trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile 
idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70(5):747-754. [http://dx.doi.org/10.1136/
ard.2010.134254]
20. De Benedetti F, Brunner H, Ruperto N, et al. Efficacy and safety of tocilizumab (TCZ) in patients with 
systemic juvenile idiopathic arthritis (SJIA): Tender 52-week data. Pediatr Rheumatol 2011;9(Suppl 
1):164. [http://dx.doi.org/10.1186/1546-0096-9-S1-P164]
21. Lovell DJ. Long-term efficacy and safety of adalimumab for up to 6 years in patients with juvenile 
idiopathic arthritis. ACR/ARHP scientific meeting, November 2011, Chicago, USA.
Online resources
Paediatric musculoskeletal matters. User-friendly and elegant resource on paediatric musculoskeletal 
conditions for students or medical personnel working with children. Developed by Prof. Helen Foster from 
Newcastle University, UK: www.pmmonline.org
